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Abstract: The straightforward enantioselective construction of the hydroquinoline ring system from 
1,5-polycarbonyl derivatives, using (R)-phenyglycinol as a chiral latent form of ammonia, is reported. 
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The process mimics the key steps believed to occur in nature in the biosynthesis of amphibian 
decahydroquinoline alkaloids. Diastereodivergent routes to enantiopure cis-2,5-disubstituted 
decahydroquinolines, including the alkaloid pumiliotoxin C (cis-195A), are developed. 
Introduction 
2,5-Disubstituted decahydroquinolines (Figure 1) represent one of the major classes of amphibian 
alkaloids,1 which were first isolated from the skin extracts of dendrobatid frogs.2 These biologically 
active natural products, unprecedented in the plant kingdom, also occur in bufonid toads,3 tunicates,4 
marine flatworms,4b and myrmicine ants.5 The biosynthetic origin of decahydroquinoline amphibian 
alkaloids remains an intriguing question and a major research challenge for chemical ecologists,1 
particularly since the isolation of some of these alkaloids from ants has opened a dietary hypothesis for 
























FIGURE 1. Amphibian cis-decahydroquinoline alkaloids. 
The structural diversity and pharmacological activities of these alkaloids, as well as the limited amounts 
available from natural sources, have stimulated considerable synthetic effort in this area,6 including 
some biomimetic approaches.7 Although there are no conclusive studies concerning their biosynthesis, it 
is thought that decahydroquinoline alkaloids might derive from the polyketide pathway, by 
aminocyclization of straight-chain 1,5-polycarbonyl derivatives A, via cyclohexenone intermediates, as 

























Mimicking these key steps believed to occur in nature, we present here a straightforward 
enantioselective construction of the hydroquinoline ring system from 1,5-polycarbonyl derivatives, using 
(R)-phenylglycinol as a chiral latent form of ammonia. Appropriate elaboration of the resulting tricyclic 
lactams results in diastereodivergent routes to enantiopure cis-2,5-disubstituted decahydroquinolines, 
including the most representative alkaloid of this group, pumiliotoxin C (cis-195A). 
 
Results and discussion 
Our biomimetic approach was inspired by a serendipitous observation when attempting a double 
phenyglycinol-induced cyclocondensation from the polycarbonyl derivative 2a in the context of model 
studies on the synthesis of (+)-anaferine (Scheme 2). 
 


































Thus, treatment of diketo diester 2a, which was prepared in excellent yield (82%) by Pd-catalyzed 
coupling of glutaryl dichloride with the functionalized organozinc derivative 1 (Scheme 3), with (R)-
phenylglycinol in refluxing benzene containing AcOH unexpectedly led to the tricyclic hydroquinoline 
lactam 5a (37% yield) instead of the desired bis(oxazolopiperidone) lactam 3 (X= H,H). Cyclohexenone 
4a (22% yield, see Scheme 4) and enaminone 6 (25% yield; ∼1:1 mixture of stereoisomers) were also 
isolated.  
 





















The formation of 5a can be rationalized by considering that the starting symmetrical diketone 2a 
undergoes an aldol cyclocondensation leading to cyclohexenone 4a, which then undergoes an in situ 
phenylglycinol-promoted cyclocondensation reaction in an overall process that parallels the biogenetic 
postulate outlined in Scheme 1. 
In accordance with this interpretation, diketo diester 2a was first converted to the intermediate 
cyclohexenone 4a (Scheme 4) in excellent yield (90%) by sequential treatment with aqueous LiOH and 





















a   R1= (CH2)3CO2Et; R2= OEt
b   R1= CH3; R2= OEt (in 2), OMe (in 4)
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The application of this biomimetic double cyclocondensation methodology to the enantioselective 
synthesis of the decahydroquinoline alkaloid cis-195A, which incorporates a C-5 methyl substituent, 
required starting from a diketoester 2b, bearing a methyl ketone moiety. This 1,5-polycarbonyl 
derivative was prepared in 65% yield by Pd-catalyzed coupling of the organozinc derivative 1 with 5-
oxohexanoyl chloride. In this series, the initial aldol cyclocondensation to 4b took place in 82% yield, 
whereas the phenylglycinol-promoted cyclocondensation stereoselectively provided tricyclic lactam 5b 
in 70% yield. The configuration of the stereogenic ring fusion carbon atoms generated in this step was 
unambiguously established by X-ray crystallographic analysis. 
The conversion of lactam 5b to the target alkaloid required the stereoselective hydrogenation of the 
carbon-carbon double bond, the introduction of the propyl substituent at C-2, and the reductive removal 
of the chiral inductor. The catalytic hydrogenation of 5b using PtO2 as the catalyst took place in nearly 
quantitative yield and complete selectivity from the most accessible face to give lactam 6, whose 
absolute configuration was unambiguously established by X-ray crystallographic analysis (Scheme 5). 
 









  X= O

















(cis-195A) R= (R)-CH(C6H5)CH2OH  9
  R= Boc 10
1. LiAlH4

























The lactam carbonyl present in tricyclic lactam 6 allows the introduction of substituents at the 2-position 
of the hydroquinoline ring, ultimately leading to enantiopure 2,5-disubstituted cis-decahydroquinolines. 
Thus, lactam 6 was converted into the corresponding thioamide, which was then subjected to 
Eschenmoser sulfide contraction10 conditions (BrCH2CO2Me; then (MeO)3P, Et3N) to give β enamino 
ester 8 in 50% overall yield. 
At this point, the complete relative stereochemistry of the target alkaloid cis-195A was installed by 
hydrogenation of 8 in the presence of PtO2 under acidic conditions (AcOH, MeOH, 24h), which brought 
about both the stereoselective reduction of the vinylogous urethane double bond11 and the cleavage of 
the oxazolidine C─O bond. A subsequent debenzylation with hydrogen and Pd(OH)2 in the presence of 
Boc2O led to the protected cis-decahydroquinoline 10. 
Finally, the conversion of ester 10 into pumiliotoxin C was accomplished in satisfactory overall yield by 
LiAlH4 reduction to alcohol 11, followed by methylenation of the corresponding aldehyde, subsequent 
catalytic hydrogenation of the resulting N-Boc-2-allyldecahydroquinoline, and finally deprotection of the 
piperidine nitrogen. The NMR spectroscopic data and [α]22D value (─15.3, c=0.5 in MeOH) of cis-195A 
(pumiliotoxin C) hydrochloride were consistent with those reported in the literature.12,13 
Unexpectedly, reversing the order of the catalytic hydrogenation of the endocyclic double bond and the 
Eschenmoser sulfide contraction reactions resulted in a dramatic change in the overall stereochemical 
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outcome of the process. Thus, catalytic hydrogenation of enamino ester 13 (PtO2, AcOH, MeOH, 16h), 
which was prepared in 76% overall yield from lactam 5b as outlined in Scheme 6, followed by reaction 
of the resulting secondary amine with Boc2O did not lead to the expected decahydroquinoline-2-acetate 
derivative 10, but to a stereoisomer, ent-2-epi-10, instead (45% overall yield).14 The configuration of 
this ester was initially misassigned as that of 2-epi-10 on the basis of the 2,8a-trans, 4a,5-trans, 4a,8a-
cis relationship (evident by X-ray crystallography) of the alcohol resulting from its LiAlH4 reduction 
and bearing in mind the known C-4a absolute configuration of the starting material 13. 
The correct absolute configurations of the above ester and alcohol were only unambiguously established 
as those depicted in Scheme 6 for ent-2-epi-10 and ent-2-epi-11, respectively, once this alcohol was 
converted to ent-2-epi-cis-195A15 following a synthetic sequence similar to that previously developed in 
the above pumiliotoxin C series. This compound showed NMR spectroscopic data16 and an [α]22D 
value12f consistent with those reported in the literature for (─)-4a,5,8a-epipumiliotoxin C.17 
 





5b  X= O



































































The formation of ent-2-epi-10 from 13 involves six chemical transformations: stereoselective 
hydrogenation of two carbon-carbon double bonds, reductive cleavage of the oxazolidine ring, 
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epimerization at the perhydroquinoline C-4a position, debenzylation and, finally, introduction of the 
protective group.  
The hydrogenation of the exocyclic C─C double bond of 13 is the first event of this multistep sequence, 
as evidenced by the rapid disappearance (3h) of the NMR singlet at δ 4.38 attributable to the vinyl 
proton α to the carbonyl group when operating under neutral conditions (PtO2, MeOH). The resulting 
intermediate B is then converted to the perhydro derivative C, as indicated by the successive 
disappearance of the NMR signals due to the exocyclic and endocyclic (broad singlet at δ 5.42) double 
bonds, when the hydrogenation was effected using Pd/C as the catalyst in methanol. Under acidic 
conditions (PtO2, MeOH, excess AcOH), this intermediate was formed in 30 min, and after prolonged 
reaction times it evolved into the secondary amine precursor of ent-2-epi-10. 
A similar stereochemical result was obtained starting from diester 16. Catalytic hydrogenation of 16 in 
the presence of PtO2 under acidic conditions (AcOH, EtOH), followed by protection of the resulting 
secondary amine with Boc2O, led to the cis-decahydroquinoline 17 (Scheme 7). Diester 16 was prepared 
in 71% overall yield from lactam 5a by Eschenmoser sulfide contraction of the corresponding 
thiolactam 15. 
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The stereochemical outcome of the hydrogenation of 13 was quite surprising because two 
configurationally related substrates (5b and 13) lead to two diastereoisomers (10 and ent-2-epi-10, 
respectively) differing in the absolute configuration of three stereocenters. This result can be rationalized 
by considering that the hydrogenation of the endocyclic C─C double bond of the conformationally rigid 
tricyclic derivatives 5b and B occurs with differing facial selectivity and that the absolute configuration 
of the stereocenter generated in this step (C-5) determines the stereochemistry of the configurationally 
labile C-4a stereocenter under the acidic conditions required for the reductive cleavage of the 
oxazolidine ring. 
A reasonable explanation for the contrasting stereoselectivity in the above hydrogenation step can be 
obtained by analyzing the most stable conformations of 5b and B obtained by molecular orbital 
calculations (Scheme 8). Thus, although the presence of an axial C─O bond in 5b directs the uptake of 
hydrogen to the opposite α face to give 6, the axial acetate chain on the concave face of the 
hydroquinoline moiety in B reverses this situation and the hydrogenation occurs on the less hindered β-
face to provide the intermediate C. 
 
SCHEME 8. Stereochemical Outcome of the C─C Double Bond Hydrogenation 
   
 
 
On the other hand, the C-4a configuration in ent-2-epi-10, opposite to that in 13, can be accounted for by 























































iminium salt Xa (Scheme 9), which is in equilibrium via the corresponding enamine with the most 
stable epimer Ya (equatorial methyl group) in a process involving the inversion of the configuration at 
the C-4a stereocenter. A subsequent stereoselective hydrogenation of the iminium function and 
debenzylation, followed by protection with Boc2O, leads to cis-decahydroquinoline ent-2-epi-10.18 
In contrast, the C-4a epimerization does not occur in the pumiliotoxin C series, in which the iminium 
intermediate Xb (equatorial methyl group), generated after an initial stereoselective reduction of the 
exocyclic double bond of 8, is directly converted to the cis-decahydroquinoline 10. 
 









































In summary, starting from an easily accessible (R)-phenylglycinol-derived tricyclic lactam 5b, 
depending on the order of the synthetic transformations (paths A or B), it is possible to 
enantioselectively access 5-substituted cis-decahydroquinoline-2-acetate derivatives that differ in the 
configuration of the 4a, 5, and 8a stereocenters (Scheme 10). 
 























































The results reported in this paper not only provide experimental support for the presumed biosynthetic 
pathway to amphibian decahydroquinoline alkaloids but also open general enantioselective routes to 
both the cis and the 2-epi-cis- series of these alkaloids, which differ in the nature of the substituents at 
the 2 and 5 positions and in the relative C-2 configuration (see Figure 1). Starting from an appropriate 
(R)-phenyglycinol-derived tricyclic lactam, the above path A provides access to the normal cis-series, 
whereas when using an (S)-phenylglycinol-derived lactam, the above path B would lead to 
decahydroquinoline alkaloids of the 2-epi-cis series (Scheme 11). 
 





































Diethyl 5,9-dioxotridecanedioate (2a). Pd[P(C6H5)3]4 (2.9 g, 2.5 mmol) was added to a solution of 4-
ethoxy-4-oxobutylzinc bromide (1; 100 mL of a 0.5 M solution in THF, 50 mmol) in THF (150 mL), 
and the mixture was stirred at rt for 30 min. Glutaryl dichloride (3.2 mL, 25 mmol) was added, and the 
mixture was stirred at rt for additional 90 min. The mixture was poured into saturated aqueous NH4Cl 
and extracted with Et2O. The combined organic extracts were washed with saturated aqueous NaCl, 
dried, and concentrated to give a solid. Flash chromatography (from 9:1 to 8:2 hexane-EtOAc) afforded 
2a (6.7 g, 82%): mp 73-74 ºC; 1H NMR (200 MHz, CDCl3) δ 1.26 (m, 6H, 2CH3), 1.88 (m, 6H), 2.32 
(m, 4H), 2.45 (m, 8H), 4.12 (m, 4H, 2CH2-ethyl); 13C NMR (50.3 MHz, CDCl3) δ 14.2 (2CH3), 17.6 
(CH2), 18.8 (2CH2), 33.3 (2CH2), 41.4 (2CH2), 41.5 (2CH2), 60.3 (2CH2), 173.0 (2COO), 209.4 
(2CO); IR (NaCl) 1735, 1721 cm-1. Anal. Calcd for C17H28O6: C 71.52, H 7.37, N 3.79; found: C 71.50, 
H 7.42, N 3.84. 
Ethyl 5,9-dioxodecanoate (2b). A mixture of oxalyl chloride (38 mL, 0.44 mol) and 5-oxohexanoic 
acid (12 mL, 0.1 mol) in anhydrous Et2O (100 mL) was stirred at rt for 6 h. The solution was 
concentrated, and the resulting residue was dried to give the acid chloride, which was used in the next 
step without further purification. A solution of 4-ethoxy-4-oxobutylzinc bromide (1; 200 mL of a 0.5 M 
solution in THF, 0.1 mol) and Pd[P(C6H5)3]4 (5.8 g, 5 mmol) in THF (400 mL) was stirred at rt for 30 
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min. Then, the above acid chloride was added, and the resulting mixture was stirred at rt for 16 h. The 
mixture was poured into saturated aqueous NH4Cl and extracted with Et2O. The combined organic 
extracts were washed with saturated aqueous NaCl, dried, and concentrated to give an oil. Flash 
chromatography (from 9:1 to 8:2 hexane-EtOAc) afforded diketoester 2b (14.8 g, 65%): 1H NMR (200 
MHz, CDCl3) δ 1.26 (t, J = 7.1 Hz, 3H, CH3-ethyl), 1.76-1.96 (m, 4H), 2.13 (s, 3H, CH3), 2.84-2.36 (m, 
2H), 2.41-2.51 (m, 6H), 4.12 (q, J = 7.1 Hz, 2H, CH2-ethyl); 13C NMR (50.3 MHz, CDCl3) δ 14.2 
(CH3-ethyl), 17.6 (CH2), 18.8 (CH2), 29.8 (CH3), 33.2 (CH2), 41.4 (2CH2), 42.4 (CH2), 60.3 (CH2-
ethyl), 172.9 (COO), 208.1 (CO), 209.4 (CO); IR (NaCl) 1715 cm-1. Anal. Calcd for C12H20O4: C 
63.14, H 8.83; found: C 63.05, H 8.91. 
Ethyl 2-(2-ethoxycarbonylethyl)-3-oxocyclohexenebutyrate (4a). A solution of LiOH·H2O (8 g, 0.2 
mol) in water (125 mL) was added to a solution of 2a (6 g, 18.3 mmol) in THF (300 mL) and EtOH 
(350 mL), and the mixture was stirred at rt for 3 h. The mixture was concentrated, and the residue was 
taken up in 2N aqueous HCl and extracted with EtOAc. The combined organic extracts were dried and 
concentrated to give 2-(2-carboxyethyl)-3-oxocyclohexenebutyric acid, which was used in the next step 
without further purification. Me3SiCl (10 mL, 80 mmol) was added to a solution of the acid in EtOH 
(105 mL), and the mixture was stirred at rt for 16 h. The mixture was concentrated, and the residue was 
taken up in EtOAc and washed with saturated aqueous NaHCO3. The combined organic extracts were 
dried and concentrated to give ketodiester 4a (5.1 g, 90%) as an oil: 1H NMR (200 MHz, CDCl3) δ 1.24 
(t, J = 7.2 Hz, 3H), 1.27 (t, J = 7.2 Hz, 3H), 1.72-2.05 (m, 4H), 2.28-2.41 (m, 10H), 2.55-2.63 (m, 2H), 
4.10 (q, J = 7.2 Hz, 2H), 4.14 (q, J = 7.2 Hz, 2H); 13C NMR (50.3 MHz, CDCl3) δ 14.1 (2CH3), 20.7 
(CH2), 22.2 (CH2), 22.9 (CH2), 30.4 (CH2), 33.5 (CH2), 33.7 (CH2), 34.0 (CH2), 37.8 (CH2), 60.0 
(CH2), 60.3 (CH2), 133.9 (C), 158.7 (C), 172.6 (COO), 172.8 (COO), 198.4 (CO); IR (NaCl) 1778, 
1664 cm-1; HRMS calcd for [C17H26O5]: 310.1780, found: 310.1778. 
Methyl 2-methyl-6-oxocyclohexenepropionate (4b). Operating as in the above preparation of 4a, from 
diketoester 2b (7.5 g, 33 mmol), LiOH·H2O (15 g, 0.35 mol),  and EtOH (375 mL) for 5h, and then 
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Me3SiCl (13 mL, 0.1 mol) and MeOH (80 mL), ketoester 4b (5.5 g, 85%) was obtained as an oil: 1H 
NMR (300 MHz, CDCl3) δ 1.88-1.96 (m, 2H), 1.97 (s, 3H, CH3), 2.33-2.40 (m, 6H), 2.59-2.64 (m, 2H), 
3.65 (s, 3H, CH3O); 13C NMR (75.4 MHz, CDCl3) δ 21.0 (CH2), 21.1 (CH3), 22.1 (CH2), 32.8 (CH2), 
33.0 (CH2), 37.7 (CH2), 51.4 (CH3O), 133.6 (C), 156.5 (C), 173.5 (COO), 198.2 (CO); IR (NaCl) 1738, 
1663 cm-1; HRMS calcd for [C11H16O3+ Na]: 219.100, found 219.099. 
Ethyl (3R,7aS,11aS)-5-oxo-3-phenyl-2,3,5,6,7,7a,10,11-octahydrooxazolo[2,3-j]quinoline-8-
butyrate (5a). (R)-Phenylglycinol (466 mg, 3.4 mmol) was added to a solution of ketodiester 4a (350 
mg, 1.1 mmol) and AcOH (0.2 mL, 3.4 mmol) in benzene (15 mL). The mixture was heated at reflux for 
48 h with azeotropic elimination of water produced by a Dean-Stark apparatus. The resulting mixture 
was cooled and concentrated. Flash chromatography (from 3:2 to 1:1 hexane-EtOAc) afforded lactam 5a 
(253 mg, 60%) as a solid and its 3R,7aR,11aR diastereomer (76 mg, 18%). 5a (higher Rf): mp 89-91 ºC; 
1H NMR (300 MHz, CDCl3, COSY, HSQC) δ 1.26 (t, J = 7.2 Hz, 3H, CH3), 1.65-1.92 (m, 4H, H-7, H-
2’), 2.07-2.11 (m, 7H, H-7a, H-10, H-11, H-1’), 2.18-2.76 (m, 4H, H-6, H-3’), 3.89 (t, J = 8.8 Hz, 1H, 
H-2), 4.13 (q, J = 7.2 Hz, 2H, CH2-ethyl), 4.56 (t, J = 8.8 Hz, 1H, H-2), 5.30-5.45 (m, 2H, H-3, H-9), 
7.17-7.37 (m, 5H, H-Ar); 13C NMR (100.6 MHz, CDCl3) δ 14.2 (CH3), 22.9 (CH2), 23.1 (CH2), 25.1 
(CH2), 26.0 (CH2), 31.4 (CH2), 33.7 (2CH2), 43.3 (C-7a), 58.5 (C-3), 60.2 (CH2-ethyl), 69.5 (C-2), 
94.3 (C-11a), 121.0 (C-9), 125.3 (CH-o), 127.1 (CH-p), 128.6 (CH-m), 136.4 (C-8), 140.3 (C-i), 169.6 
(COO), 173.5 (COO); IR (NaCl) 1731, 1655 cm-1; [α]22D −97.3 (c 1.0, MeOH). Anal. Calcd for 
C23H29NO4: C 72.04, H 7.62, N 3.65; found: C 71.63, H 7.62, N 3.53. 7aR,11aR-epi-5a (lower Rf): 1H 
NMR (200 MHz, CDCl3) δ 1.27 (t, J = 7.2 Hz, 3H, CH3), 1.61-1.97 (m, 4H), 2.00-2.48 (m, 11H), 3.93 
(dd, J = 9.2, 1H, 1.8 Hz, H-2), 4.15 (q, J = 7.2 Hz, 2H, CH2-ethyl), 4.41 (dd, J = 9.2, 1H, 7.2 Hz, H-2), 
4.98 (dd, J = 7.2, 1H, 1.8 Hz, H-3), 5.45 (s, 1H, H-9), 7.26-7.31 (m, 5H, H-Ar); 13C NMR (75.4 MHz, 
CDCl3) δ 14.1 (CH3), 23.0 (CH2), 23.3 (CH2), 25.7 (CH2), 26.0 (CH2), 30.5 (CH2), 33.6 (CH2), 33.9 
(CH2), 42.3 (C-7a), 59.3 (C-3), 60.1 (CH2-ethyl), 70.9 (C-2), 93.6 (C-11a), 120.0 (C-9), 126.1 (CH-o), 
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127.2 (CH-p), 128.4 (CH-m), 137.5 (C-8), 141.6 (C-i), 167.1 (COO), 173.4 (COO); IR (NaCl) 1731, 
1657 cm-1; [α]22D +53.1 (c 0.9, MeOH); HRMS calcd for [C23H29NO4]: 383.2097, found: 383.2099. 
(3R,7aS,11aS)-8-Methyl-5-oxo-3-phenyl-2,3,5,6,7,7a,10,11-octahydrooxazolo[2,3-j]quinoline (5b). 
Operating as in the above preparation of 5a, from ketoester 4b (9.5 g, 48 mol), (R)-phenylglycinol (20 g, 
145 mol), and AcOH (8.3 mL, 145 mol) in benzene (750 mL), lactam 5b (9.5 g, 70%) and its  
3R,7aR,11aR diastereomer (2.4 g, 19%) were obtained after flash chromatography (from 3:2 to 1:1 
hexane-EtOAc). 5b (higher Rf): mp 115-120 ºC; 1H NMR (300 MHz, CDCl3, COSY, HSQC) δ 1.59-
1.79 (m, 2H, H-7, H-11), 1.78 (s, 3H, CH3), 1.86 (dd, J = 13.2, 1H, 6.6 Hz, H-11), 1.96-2.13 (m, 3H, H-
7a, H-10), 2.20-2.29 (m, 1H, H-7), 2.44-2.56 (m, 1H, H-6), 2.70 (dd, J = 18.6, 1H, 6.0 Hz, H-6), 3.91 (t, 
J = 8.5 Hz, 1H, H-2), 4.57 (t, J = 8.5 Hz, 1H, H-2), 5.44-5.50 (m, 2H, H-3, H-9), 7.18-7.36 (m, 5H, H-
Ar); 13C NMR (75.4 MHz, CDCl3) δ 21.5 (CH3), 22.9 (C-10), 24.7 (C-7), 25.7 (C-11), 31.3 (C-6), 44.8 
(C-7a), 58.3 (C-3), 69.4 (C-2), 94.3 (C-11a), 120.9 (C-9), 125.1 (CH-o), 127.0 (CH-p), 128.4 (CH-m), 
133.0 (C-8), 140.2 (C-i), 169.6 (NCO); IR (NaCl) 1657 cm-1; [α]22D −102.6 (c 1.1, MeOH). Anal. Calcd 
for C18H21NO2: C 76.29, H 7.47, N 4.94; found: C 76.60, H 7.52, N, 4.92. 7aR,11aR-epi-5b (lower Rf): 
1H NMR (300 MHz, CDCl3) δ 1.56-1.72 (m, 2H), 1.82 (s, 3H, CH3), 1.96-2.45 (m, 7H), 3.94 (dd, J = 
9.0, 2.0 Hz, 1H, H-2), 4.42 (dd, J = 9.0, 7.5 Hz, 1H, H-2), 4.98 (dd, J = 7.5, 2.0 Hz, 1H, H-3), 5.45 (s, 
1H, H-9), 7.20-7.35 (m, 5H, H-Ar); 13C NMR (75.4 MHz, CDCl3) δ 21.7 (CH3), 23.4 (CH2), 25.6 
(CH2), 25.8 (CH2), 30.7 (C-6), 43.9 (C-7a), 59.4 (C-3), 71.1 (C-2), 93.8 (C-11a), 120.2 (C-9), 126.2 
(CH-o), 127.4 (CH-p), 128.5 (CH-m), 134.4 (C-8), 141.8 (C-i), 167.3 (NCO); IR (NaCl) 1657 cm-1; 
[α]22D +13.7 (c 1.2, MeOH). Anal. Calcd for C18H21NO2: C 76.29, H 7.47, N 4.94; found: C 76.25, H 
7.54, N 4.83. 
(3R,7aS,8R,11aS)-8-Methyl-5-oxo-3-phenyldecahydrooxazolo[2,3-j]quinoline (6). A solution of 
lactam 5b (2 g, 7.1 mmol) in MeOH (150 mL) containing 40% PtO2 (0.8 g) was stirred under hydrogen 
at rt for 24 h. The catalyst was removed by filtration and washed with MeOH. The combined organic 
solutions were concentrated, and the resulting oil was chromatographed (98:2 hexane-Et2O) affording 
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pure compound 6 (1.98 g, 98%) as a colorless solid: mp 81-84 ºC; 1H NMR (400 MHz, CDCl3, COSY, 
HSQC) δ 1.21  (d, J = 7.6 Hz, 3H, 3H, CH3), 1.35-1.44 (m, 2H, H-10, H-11), 1.57-1.83 (m, 6H, H-7, H-
7a, H-9, H-10, H-11), 1.90-1.98 (m, 1H, H-8), 2.08-2.19 (m, 1H, H-7), 2.46 (ddd, J = 18.4, 11.2, 7.6 Hz, 
1H, H-6), 2.63 (dd, J = 18.4, 7.6 Hz, 1H, H-6), 3.84 (t, J = 8.4 Hz, 1H, H-2), 4.52 (t, J = 8.4 Hz, 1H, H-
2), 5.30 (t, J = 8.4 Hz, 1H, H-3), 7.15-7.33 (m, 5H, H-Ar); 13C NMR (100.6 MHz, CDCl3) δ 17.7 (C-
10), 20.2 (CH3), 24.8 (C-7), 26.4 (C-11), 30.3 (C-9), 31.2 (C-6), 34.2 (C-8), 45.2 (C-7a), 57.9 (C-3), 
69.7 (C-2), 95.5 (C-11a), 125.3 (CH-o), 127.0 (CH-p), 128.5 (CH-m), 140.3 (C-i), 169.4 (NCO); IR 
(NaCl) 1654 cm-1; [α]22D −113.5 (c 1.0, MeOH); Anal. Calcd for C18H23NO2: C 75.76, H 8.12, N 4.91; 
found: C 75.86, H 8.06, N 4.88. 
(3R,7aS,8R,11aS)-8-Methyl-3-phenyl-5-thiodecahydrooxazolo[2,3-j]quinoline (7). Lawesson’s 
reagent (640 mg, 1.6 mmol) was added to a solution of saturated lactam 6 (718 mg, 2.5 mmol) in 
benzene (50 mL). The resulting mixture was heated at reflux for 3 h, cooled, and concentrated to give an 
oil. Flash chromatography (9:1 hexane-EtOAc) afforded 7 (500 mg, 66%): 1H NMR (400 MHz, CDCl3, 
COSY, HSQC) δ 1.20  (d, J = 7.2 Hz, 3H, CH3), 1.37-1.47 (m, 2H, H-10, H-11), 1.58-1.79 (m, 5H, H-7, 
H-7a, H-9, H-10, H-11), 1.84-1.90 (m, 1H, H-9), 1.92-1.98 (m, 1H, H-8), 1.99-2.11 (m, 1H, H-7), 3.08-
3.26 (m, 2H, H-6), 3.94 (t, J = 8.6 Hz, 1H, H-2), 4.59 (t, J = 8.6 Hz, 1H, H-2), 5.79 (t, J = 8.6 Hz, 1H, 
H-3), 7.10-7.12 (m, 2H, H-Ar), 7.22-7.34 (m, 3H, H-Ar); 13C NMR (100.6 MHz, CDCl3) δ 17.6 (C-10), 
20.0 (CH3), 24.7 (C-7), 26.0 (C-11), 29.2 (C-9), 34.2 (C-8), 40.7 (C-6), 44.2 (C-7a), 63.5 (C-3), 69.2 (C-
2), 97.6 (C-11a), 125.4 (CH-o), 127.1 (CH-p), 128.5 (CH-m), 138.7 (C-i), 198.3 (NCS); IR (NaCl) 1452 
cm-1; [α]22D −138.1 (c 1.5, MeOH); HRMS calcd for [C18H23NSO + H] 302.1579; found: 302.1573. 
(3R,7aS,8R,11aS)-5-(Methoxycarbonylmethylene)-8-methyl-3-phenyldecahydrooxazolo[2,3-
j]quinoline (8). A solution of 7 (1.4 g, 4.7 mmol) and methyl bromoacetate (4.3 mL, 46.5 mmol) in 
CHCl3 (18 mL) was stirred at rt for 17 h in the dark. The mixture was concentrated, and the residue was 
taken up with CHCl3 (18 mL). Trimethyl phosphite (2.2 mL, 18.6 mmol) and Et3N (6 mL) were added, 
and the resulting solution was heated at reflux for 24 h. The mixture was allowed to cool to rt and 
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concentrated. The residue was chromatographed (9:1 hexane-EtOAc) to afford 8 (1.2 g, 75%) as an oil: 
1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 1.18  (d, J = 7.2 Hz, 3H, CH3), 1.33-1.43 (m, 2H, H-10, 
H-11), 1.56-1.99 (m, 8H, H-7, H-7a, H-8, H-9, H-10, H-11), 3.11-3.21 (m, 1H, H-6), 3.25-3.37 (m, 1H, 
H-6), 3.49 (s, 3H, CH3O), 3.70 (t, J = 8.4 Hz, 1H, H-2), 4.29 (s, 1H, H-1’), 4.51 (t, J = 8.4 Hz, 1H, H-2), 
4.73 (t, J = 8.4 Hz, 1H, H-3), 7.11-7.17 (m, 2H, H-Ar), 7.23-7.36 (m, 3H, H-Ar); 13C NMR (100.6 MHz, 
CDCl3) δ 17.9 (C-10), 20.2 (CH3), 23.9 (C-7), 26.1 (C-6), 26.2 (C-11), 30.2 (C-9), 34.5 (C-8), 44.7 (C-
7a), 49.8 (CH3O), 61.7 (C-3), 70.2 (C-2), 84.7 (C-1’), 96.0 (C-11a), 125.3 (CH-o), 127.4 (CH-p), 128.8 
(CH-m), 139.2 (C-i), 159.0 (C-5), 169.0 (COO); IR (NaCl) 1788 cm-1; [α]22D −132.2 (c 0.5, MeOH); 
HRMS calcd for [C21H27NO3 + H]: 342.2069; found: 342.2063. 
(2R,4aS,5R,8aR)-1-[(R)-2-Hydroxy-1-phenylethyl]-2-(methoxycarbonylmethyl)-5-
methyldecahydroquinoline (9). A solution of 8 (340 mg, 1.0 mmol) and AcOH (2.5 mL, 44 mmol) in 
MeOH (25 mL) containing 40% PtO2 (14 mg) was stirred under hydrogen at rt for 24 h. The catalyst 
was removed by filtration through a Celite pad, the filtrate was concentrated, and the residue was taken 
up with EtOAc. The organic solution was washed with 10% aqueous KOH, dried, and concentrated. The 
resulting oil was chromatographed (from 9:1 to 8:2 hexane-EtOAc) to afford 9 (170 mg, 50%): 1H NMR 
(400 MHz, CDCl3, COSY, HSQC) δ 0.91 (d, J = 7.2 Hz, 3H, CH3), 1.12-1.20 (m, 3H, H-4, H-6, H-7), 
1.24-1.33 (m, 1H, H-8), 1.35-1.51 (m, 5H, H-3, H-4a, H-6, H-7, H-8), 1.52-1.67 (m, 2H, H-3, H-5), 1.74 
(qd, J = 13.2, 3.6 Hz, 1H, H-4), 2.49 (dd, J = 14.4, 9.2 Hz, 2H, H-1’’), 2.68 (dd, J = 14.4, 4.8 Hz, 1H, H-
1’’), 2.86-2.96 (m, 1H, H-8a), 3.54-3.63 (m, 1H, H-2), 3.64-3.71 (m, 1H, H-1’), 3.70 (s, 3H, CH3), 3.84-
3.94 (m, 1H, H-1’), 7.21-7.38 (m, 5H, H-Ar); 13C NMR (100.6 MHz, CDCl3) δ 19.2 (CH3), 20.9 (C-7), 
21.4 (C-4), 27.1 (C-6), 28.5 (C-3), 29.3 (C-8), 34.5 (C-5), 39.2 (C-1’’), 42.0 (C-4a), 49.3 (C-2), 51.6 
(CH3O), 55.5 (C-8a), 62.5 (C-2’), 68.9 (C-1’), 127.6 (CH-o), 128.3 (CH-p), 128.4 (CH-m), 140.6 
(NCO), 173.4 (COO); IR (NaCl) 2925, 1736 cm-1; [α]22D −10.9 (c 1.4, MeOH); HRMS calcd for 




methyldecahydroquinoline (10). A solution of 8 (560 mg, 1.6 mmol) and AcOH (4.1 mL, 69 mmol) in 
MeOH (40 mL) containing 40% PtO2 (230 mg) was stirred under hydrogen at rt for 24 h. The catalyst 
was removed by filtration through a Celite pad, the filtrate was concentrated, and the residue was taken 
up with EtOAc. The organic solution was washed with 10% aqueous KOH, dried, and concentrated, 
affording an oil, which was used without further purification in the next step. A solution of the oil and 
di-tert-butyl dicarbonate (700 mg, 3.2 mmol) in MeOH (30 ml) containing 40% Pd(OH)2/C (200 mg) 
was stirred under hydrogen at rt for 16 h. The catalyst was removed by filtration through a Celite pad, 
and the filtrate was concentrated. The residue was chromatographed (9:1 hexane-Et2O) to afford 
unsaturated ester 10 (280 mg, 54%) as an oil: 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 1.06  (d, J 
= 7.2 Hz, 3H, CH3), 1.25-1.30 (m, 2H, H-3, H-4), 1.44-1.53 (m, 6H, H-3, H-4a, H-6, H-7), 1.46 (s, 9H, 
tBu), 1.67-1.71 (m, 2H, H-8), 1.78-1.84 (m, 2H, H-4, H-5), 2.45 (dd, J = 14.7, 3.3 Hz, 1H, H-1’), 2.63 
(dd, J = 14.7, 10.5 Hz, 1H, H-1’), 3.67 (s, 3H, CH3O), 4.17-4.21 (m, 1H, H-8a), 4.48-4.55 (m, 1H, H-2); 
13C NMR (100.6 MHz, CDCl3) δ 19.3 (CH3), 20.3 (C-7), 20.9 (C-4), 26.7 (C-3), 28.4 (C-6), 28.5 (CH3-
tBu), 28.5 (C-8), 34.4 (C-5), 39.6 (C-1’), 41.6 (C-4a), 47.1 (C-2), 49.3 (C-8a), 51.6 (CH3O), 79.5 (C-
tBu), 155.0 (NCO), 172.1 (COO); IR (NaCl) 1740, 1687 cm-1; [α]22D −25.9 (c 0.9, MeOH);  HRMS 
calcd for [C18H31NO4 + H]: 326.2331; found: 326.2335.  
(2R,4aS,5R,8aR)-1-(tert-Butoxycarbonyl)-2-(2-hydroxyethyl)-5-methyldecahydroquinoline (11). 
LiAlH4 (200 mg, 5.3 mmol) was slowly added to a cooled solution (0 ºC) of 10 (173 mg, 0.53 mmol) in 
anhydrous THF (5 mL), and the mixture was stirred at rt for 1 h. The reaction was quenched with water, 
and the resulting mixture was extracted with EtOAc. The organic extracts were dried and concentrated, 
and the resulting residue was chromatographed (8:2 hexane-EtOAc) to give alcohol 11 (150 mg, 94%) 
as an oil: 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 1.06  (d, J = 7.2 Hz, 3H, CH3), 1.25-1.31 (m, 
3H, H-3, H-4), 1.42-1.53 (m, 5H, H-3, H-4a, H-6, H-7), 1.48 (s, 9H, tBu), 1.59-1.65 (m, 3H, H-1’, H-6, 
H-8), 1.75-1.86 (m, 4H, H-1’, H-5, H-8), 3.40 (br s, 1H, H-2’), 3.58 (br s, 1H, H-2’), 4.20 (br s, 1H, H-
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8a), 4.33 (br s, 1H, H-2); 13C NMR (100.6 MHz, CDCl3) δ 19.1 (CH3), 20.3 (C-7), 21.4 (C-4), 26.7 (C-
3), 28.3 (CH3-tBu), 28.7 (C-6), 30.1 (C-8), 34.3 (C-5), 38.4 (C-1’), 42.0 (C-4a), 45.8 (C-2), 49.8 (C-8a), 
58.9 (C-2’), 80.0 (C-tBu), 156.8 (NCO); IR (NaCl) 3449, 1659 cm-1; [α]22D +15.5 (c 1.0, MeOH); 
HRMS calcd for [C17H31NO3 + H]: 298.2382; found: 298.2376.  
(-)-Pumiliotoxin C. Dess-Martin reagent (360 mg, 0.86 mmol) was added to a solution of alcohol 11 
(180 mg, 0.61 mmol) in anhydrous CH2Cl2 (5 mL), and the mixture was stirred at rt for 2.5 h. Then, 
Et2O (9 mL), 1M aqueous Na2S2O4 (2 mL), and saturated aqueous NaHCO3 (2 mL) were added, and 
the resulting mixture was stirred for 45 min. The aqueous layer was extracted with Et2O, and the 
combined organic extracts were washed with brine, dried, and concentrated to give the corresponding 
aldehyde as an oil, which was used without further purification in the next step. BuLi (0.9 mL of a 1.6 M 
solution in hexane, 1.4 mmol) was added to a solution of methyltriphenylphosphonium bromide (535 
mg, 1.5 mmol) in THF (5 mL) at 0 ºC, and the mixture was stirred for 1.5 h. Then, a solution of the 
above aldehyde in THF (2 mL) was added, and the resulting mixture was stirred at rt for 16 h. Saturated 
aqueous NH4Cl was added, and the resulting mixture was extracted with CH2Cl2. The combined 
organic extracts were washed with saturated aqueous NaCl, dried, and concentrated. The residue was 
chromatographed (95:5 hexane-EtOAc) to give (2R,4aS,5R,8aR)-2-allyl-1-(tert-butoxycarbonyl)-5-
methyldecahydroquinoline (114 mg, 64%) as an oil: 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 1.07  
(d, J = 7.2 Hz, 3H, CH3), 1.20-1.37 (m, 3H, H-3, H-7), 1.42-1.50 (m, 5H, H-3, H-4, H-4a, H-6), 1.46 (s, 
9H, tBu), 1.50-1.84 (m, 4H, H-5, H-6, H-8), 2.23-2.32 (m, 2H, H-1’), 4.02-4.10 (m, 1H, H-2), 4.18-4.25 
(m, 1H, H-8a), 4.99-5.05 (m, 2H, H-3’), 5.70-5.81 (m, 1H, H-2’); 13C NMR (100.6 MHz, CDCl3) δ 19.4 
(CH3), 20.4 (C-4), 21.1 (C-7), 26.8 (C-3), 27.2 (C-6), 28.5 (CH3-tBu), 28.6 (C-8), 34.5 (C-5), 40.0 (C-
1’), 41.9 (C-4a), 49.3 (C-2), 50.2 (C-8a), 79.1 (C-tBu), 116.5 (C-3’), 136.7 (C-2’), 155.7 (NCO); IR 
(NaCl) 1686 cm-1; [α]22D +4.7 (c 0.8, MeOH);  HRMS calcd for [C18H31NO2 +Na]: 316.2252; found: 
316.2247. A solution of the above alkene (60 mg, 0.2 mmol) in MeOH (7 mL) containing 40% PtO2 (25 
mg) was stirred under hydrogen at rt for 1 h. The catalyst was removed by filtration and washed with 
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MeOH. The combined organic solutions were concentrated, and the resulting oil was chromatographed 
(98:2 hexane-Et2O) affording pure (2S,4aS,5R,8aR)-1-(tert-butoxycarbonyl)-5-methyl-2-
propyldecahydroquinoline (56 mg, 95%) as an oil: 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 0.92 
(t, J = 7.0 Hz, 3H, H-3’), 1.06  (d, J = 7.2 Hz, 3H, CH3), 1.20-1.26 (m, 3H, H-3, H-4), 1.40-1.56 (m, 9H, 
H-1’, H-2’, H-3, H-4a, H-7, H-8), 1.46 (s, 9H, tBu), 1.62-1.67 (m, 2H, H-6), 1.77-1.84 (m, 2H, H-4, H-
5), 4.00 (br s, 1H, H-8a), 4.20 (br s, 1H, H-2); 13C NMR (100.6 MHz, CDCl3) δ 14.2 (C-3’), 19.3 
(CH3), 20.4 (C-2’), 20.8 (C-7), 21.4 (C-4), 26.8 (C-3), 28.0 (C-6), 28.5 (C-8), 28.5 (CH3-tBu), 34.6 (C-
5), 37.9 (C-1’), 42.1 (C-4a), 49.2 (C-2), 50.3 (C-8a), 78.9 (C-tBu), 155.4 (NCO); IR (NaCl) 1686 cm-1; 
[α]22D +18.8 (c 1.5, MeOH); HRMS calcd for [C18H33NO2 + H]: 296.2590; found: 296.2584. To a 
solution of the above saturated compound (50 mg, 0.17 mmol) in anhydrous CH2Cl2 (0.5 mL) was 
added TFA (0.5 mL, 6.5 mmol), and the mixture was stirred at rt for 15 min. Then, CH2Cl2 (3 mL) was 
added, and the solution was washed with 10% aqueous KOH, dried, and filtered. 1M HCl in MeOH was 
added to the filtrate, and the solution was concentrated to give (−)-pumiliotoxin C hydrochloride (39 
mg, 99%) as a colorless solid: mp 248-250 ºC; 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 0.90 (d, J 
=  6.4 Hz, 3H, CH3); 0.92  (t, J = 7.4 Hz, 3H, H-3’), 0.97-1.03 (m, 1H, H-6), 1.22-1.27 (m, 1H, H-2’), 
1.40-1.45 (m, 4H, H-2’, H-3, H-4a, H-7), 1.46-1.62 (m, 2H, H-4, H-8), 1.76-1.88 (m, 2H, H-4, H-6), 
2.07-2.17 (m, 4H, H-1’, H-3, H-5), 2.33-2.50 (m, 2H, H-7, H-8), 2.98 (br s, 1H, H-2), 3.32 (br s, 1H, H-
8a), 8.40 (br s, 1H, NH), 9.45 (br s, 1H, NH); 13C NMR (100.6 MHz, CDCl3) δ 13.7 (C-3’), 19.1 
(C-2’), 19.7 (CH3), 20.4 (C-7), 23.1 (C-4), 25.1 (C-3), 27.1 (C-5), 29.1 (C-8), 34.3 (C-1’), 34.8 (C-6), 
40.8 (C-4a), 58.0 (C-8a), 60.1 (C-2); IR (NaCl) 2930, 2872 cm-1; [α]22D −15.3 (c 0.5, MeOH). 
(3R,7aS,11aS)-8-Methyl-3-phenyl-5-thio-2,3,5,6,7,7a,10,11-octahydrooxazolo[2,3-j]quinoline (12). 
Operating as in the preparation of 7, from lactam 5b (2.4 g, 8.5 mmol) and Lawesson’s reagent (2.1 g, 
5.3 mmol), thiolactam 12 (2.35 g, 93%) was obtained as a solid after flash chromatography (9:1 hexane-
EtOAc): mp 117-122 ºC; 1H NMR (200 MHz, CDCl3, COSY, HETCOR) δ 1.57-1.75 (m, 1H, H-7), 
1.76-1.81 (m, 1H, H-11), 1.78 (s, 3H, CH3), 1.85-1.98 (m, 1H, H-11), 1.98-2.18 (m, 2H, H-10), 2.20-
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2.28 (m, 2H, H-7, H-7a),  3.03-3.19 (m, 1H, H-6), 3.21-3.38 (m, 1H, H-6), 4.00 (dd, J = 8.8, 7.8 Hz, 1H, 
H-2), 4.63 (t, J = 8.8 Hz, 1H, H-2), 5.45 (s, 1H, H-9), 5.96 (t, J = 7.8 Hz, 1H, H-3), 7.11-7.16 (m, 2H, 
H-Ar), 7.26-7.39 (m, 3H, H-Ar); 13C NMR (75.4 MHz, CDCl3) δ 21.5 (CH3), 22.8 (C-10), 25.0 (C-11), 
25.3 (C-7), 40.7 (C-6), 44.1 (C-7a), 64.1 (C-3), 69.0 (C-2), 96.0 (C-11a), 120.4 (C-9), 125.2 (CH-o), 
127.1 (CH-p), 128.5 (CH-m), 133.5 (C-8), 138.6 (C-i), 199.0 (NCS); IR (NaCl) 1450 cm-1; [α]22D 
−209.1 (c 0.6, MeOH); HRMS calcd for [C18H21NOS]: 299.1344; found: 299.1347. 
(3R,7aS,11aS)-5-(Methoxycarbonylmethylene)-8-methyl-3-phenyl-2,3,5,6,7,7a,10,11-
octahydrooxazolo[2,3-j]quinoline (13). Operating as in the preparation of 8, from thiolactam 12 (700 
mg, 2.34 mmol), methyl bromoacetate (2 mL, 23.4 mmol) in CHCl3 (10 mL), and then trimethyl 
phosphite (1.1 mL, 9.4 mmol) and Et3N (3 mL), compound 13 (650 mg, 82%) was obtained as an oil 
after flash chromatography (7:3 hexane-EtOAc): 1H NMR (300 MHz, CDCl3, COSY, HETCOR) δ 
1.45-1.59 (m, 1H, H-7), 1.72-1.83 (m, 1H, H-11), 1.77 (s, 3H, CH3), 1.80-2.10 (m, 4H, H-7a, H-10, H-
11), 2.20-2.30 (m, 1H, H-7), 3.15-3.39 (m, 2H), 3.50 (s, 3H, CH3O), 3.77 (t, J = 8.5 Hz, 1H, H-2), 4.38 
(s, 1H, CH=), 4.55 (t, J = 8.5 Hz, 1H, H-2), 4.86 (t, J = 8.5 Hz, 1H, H-3), 5.42 (s, 1H, H-9), 7.15-7.18 
(m, 2H, H-Ar), 7.27-7.38 (m, 3H, H-Ar); 13C NMR (75.4 MHz, CDCl3) δ 21.6 (CH3), 23.0 (C-10), 24.4 
(C-7), 25.9 (C-11), 26.4 (C-6), 44.7 (C-7a), 49.9 (CH3O), 62.6 (C-3), 70.0 (C-2), 85.3 (CH=), 94.5 (C-
11a), 120.2 (C-9), 125.2 (CH-o), 127.5 (CH-p), 128.9 (CH-m), 134.2 (C-8), 139.2 (C-i), 159.3 (C-5), 
168.8 (COO); IR (NaCl) 1739 cm-1; [α]22D −155.2 (c 0.8, MeOH); HRMS calcd for [C21H25NO3]: 
339.1834; found: 339.1832. 
(2R,4aR,5S,8aS)-1-(tert-Butoxycarbonyl)-2-(methoxycarbonylmethyl)-5-
methyldecahydroquinoline (ent-2-epi-10). A solution of 13 (100 mg, 0.3 mmol) and AcOH (0.9 mL, 
15 mmol) in MeOH (10 mL) containing 40% PtO2 (40 mg) was stirred under hydrogen at rt for 16 h. 
The catalyst was removed by filtration, the filtrate was concentrated, and the residue was taken up with 
EtOAc and extracted with 2N aqueous HCl. The aqueous solution was basified with saturated aqueous 
NaHCO3 and extracted with EtOAc. These organic extracts were dried and concentrated to give an oil, 
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which was used without further purification in the next step. A solution of the oil and di-tert-butyl 
dicarbonate (65 mg, 0.3 mmol) and Et3N (50 µl, 0.3 mmol) in CH2Cl2 (5 ml) was stirred under 
hydrogen at rt for 16 h. The solution was washed with 2N aqueous HCl, dried, and concentrated. The 
resulting residue was chromatographed (9:1 hexane-EtOAc) to afford ent-2-epi-10 (43 mg, 45%) as an 
oil: 1H NMR (300 MHz, CDCl3, COSY, HETCOR) δ 0.78-0.86 (m, 2H, H-4), 0.99 (d, J = 7.3 Hz, 3H, 
CH3), 1.14-1.23 (m, 2H, H-6), 1.39 (s, 9H, tBu), 1.48-1.91 (m, 8H, H-3, H-4a, H-5, H-7, H-8), 2.40 (dd, 
J = 15.0, 10.0 Hz, 1H, H-1’), 2.65 (dd, J = 15.0, 4.0 Hz, 1H, H-1’), 3.60 (s, 3H, CH3O), 3.84 (dt, J = 
12.0, 4.5 Hz, 1H, H-8a), 4.12-4.19 (m, 1H, H-2); 13C NMR (75.4 MHz, CDCl3) δ 19.0 (CH3), 19.7 (C-
4), 19.9 (C-7), 24.0 (C-3), 25.9 (C-6), 28.5 (3CH3-tBu), 29.7 (C-8), 33.2 (C-5), 36.8 (C-4a), 39.9 (C-1’), 
48.0 (C-2), 50.1 (C-8a), 51.5 (CH3O), 79.4 (C-tBu), 154.8 (COO), 172.1 (COO); IR (NaCl) 1740, 1690 
cm-1; [α]22D −5.1 (c 0.9, MeOH). Anal. Calcd for C18H31NO4: C 66.43, H 9.60, N 4.30; found: C 66.79, 
H 9.90, N 4.26. 
(2R,4aR,5S,8aS)-1-(tert-Butoxycarbonyl)-2-(2-hydroxyethyl)-5-methyldecahydroquinoline (ent-2-
epi-11). Operating as in the preparation of 11, from ent-2-epi-10 (1.4 g, 4.3 mmol) and LiAlH4 (1.7 g, 
43.8 mmol), alcohol ent-2-epi-11 (1.2 g, 94%) was obtained as a solid after flash chromatography (from 
9:1 to 8:2 hexane-EtOAc): mp 85-89 ºC; 1H NMR (300 MHz, CDCl3, COSY, HETCOR) δ 1.05 (d, J = 
7.5 Hz, 3H, CH3), 1.13-1.27 (m, 3H, H-6, H-8), 1.41-1.45 (m, 3H, H-4, H-7), 1.48 (s, 9H, tBu), 1.58-
1.78 (m, 5H, H-3, H-4, H-5, H-1’), 1.84-1.94 (m, 2H, H-4a, H-8), 1.96-2.06 (m, 1H, H-3), 3.47-3.65 (m, 
2H, H-2’), 3.80 (dt, J = 12, 4.2 Hz, 1H, H-8a), 4.06-4.16 (m, 1H, H-2); 13C NMR (75.4 MHz, CDCl3) δ 
19.1 (CH3), 19.5 (C-4), 19.7 (C-7), 25.0 (C-3), 25.9 (C-6), 28.4 (3CH3-tBu), 29.9 (C-8), 32.8 (C-5), 35.9 
(C-4a), 39.6 (C-1’), 46.8 (C-2), 50.8 (C-8a), 59.1 (C-2’), 79.7 (C-tBu), 156.7 (NCO); IR (NaCl) 3450, 
1662 cm-1; [α]22D −0.8 (c 1.0, MeOH). Anal. Calcd for C17H31NO3: C 68.65, H 10.51, N 4.71; found: C 
68.62, H 10.85, N 4.62. 
ent-2-epi-Pumiliotoxin C. Operating as in the pumiliotoxin C series, from alcohol ent-2-epi-11 (180 
mg, 0.61 mmol) and Dess-Martin reagent (365 mg, 0.86 mmol), (2R,4aR,5S,8aS)-1-(tert-
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butoxycarbonyl)-5-methyl-2-(2-oxoethyl)decahydroquinoline (140 mg, 78%) was obtained as a solid 
after flash chromatography (95:5 hexane-EtOAc): mp 81-85 ºC; 1H NMR (300 MHz, CDCl3, COSY, 
HETCOR) δ 0.85-0.93 (m, 1H, H-4), 1.07 (d, J = 7.2 Hz, 3H, CH3), 1.19-1.34 (m, 3H, H-6, H-8), 1.45 
(s, 9H, tBu), 1.58-2.06 (m, 8H, H-3, H-4, H-4a, H-5, H-7, H-8),  2.56 (ddd, J = 16.0, 7.5, 2.1 Hz, 1H, H-
1’), 2.78 (ddd, J = 16.0, 5.7, 2.1 Hz, 1H, H-1’), 3.94 (dt, J = 12.0, 4.5 Hz, 1H, H-8a), 4.28-4.35 (m, 1H, 
H-2), 9.75 (t, J = 2.1 Hz, 1H, H-2’); 13C NMR (75.4 MHz, CDCl3) δ 19.0 (CH3), 19.7 (C-4), 20.3 (C-7), 
25.7 (C-3), 25.9 (C-6), 28.4 (3CH3-tBu), 29.4 (C-8), 33.2 (C-5), 37.1 (C-4a), 46.0 (C-2), 50.1 (C-1’), 
50.4 (C-8a), 79.6 (C-tBu), 154.9 (NCO), 200.7 (CO); IR (NaCl) 1725, 1686 cm-1; [α]22D −5.2 (c 0.9, 
MeOH); HRMS calcd for [C17H29NO3 + Na]: 318.2045; found: 318.2040. Operating as in the previous 
series, from the above aldehyde (100 mg, 0.34 mmol), BuLi (0.4 mL of a 1.6 M solution in hexane, 0.63 
mmol), and methyltriphenylphosphonium bromide (243 mg, 0.68 mmol) in THF (2.7 mL), 
(2R,4aR,5S,8aS)-2-allyl-1-(tert-butoxycarbonyl)-5-methyldecahydroquinoline (70 mg, 70%) was 
obtained as an oil after flash chromatography (95:5 hexane-EtOAc): 1H NMR (300 MHz, CDCl3, 
COSY, HETCOR) δ 0.81-0.84 (m, 1H, H-4), 0.99 (d, J = 7.2 Hz, 3H, CH3), 1.03-1.19 (m, 3H, H-6, H-
8), 1.40 (s, 9H, tBu), 1.42-1.88 (m, 8H, H-3, H-4, H-4a, H-5, H-7, H-8), 2.03-2.22 (m, 1H, H-1’),  2.32-
2.40 (m, 1H, H-1’), 3.66 (m, 1H, H-2), 3.82 (dt, J = 12.3, 4.5 Hz, 1H, H-8a), 4.92-5.01 (m, 2H, H-3’), 
5.62-5.76 (m, 1H, H-2’); 13C NMR (75.4 MHz, CDCl3) δ 19.1 (CH3), 19.6 (C-4), 19.7 (C-7), 22.1 (C-
3), 25.9 (C-6), 28.5 (3CH3-tBu), 29.9 (C-8), 33.2 (C-5), 36.6 (C-4a), 39.9 (C-1’), 49.9 (C-8a), 50.8 (C-
2), 78.9 (C-tBu), 116.4 (C-3’), 136.2 (C-2’), 155.0 (NCO); IR (NaCl) 1688 cm-1; [α]22D −2.1 (c 1.0, 
MeOH); HRMS calcd for [C18H31NO2 + Na]: 316.2247; found: 316.2236.  A solution of the above 
alkene (60 mg, 0.2 mmol) in MeOH (7 mL) containing 40% Pd-C (25 mg) was stirred under hydrogen at 
rt for 1 h. After the usual work-up, flash chromatography (98:2 hexane-Et2O) afforded pure 
(2S,4aR,5S,8aS)-1-(tert-butoxycarbonyl)-5-methyl-2-propyldecahydroquinoline (57 mg, 97%) as an oil: 
1H NMR (400 MHz, CDCl3, COSY, HETCOR) δ 0.92 (t, J = 7.2 Hz, 4H, CH3, H-4), 1.05 (d, J = 7.2 
Hz, 3H, CH3), 1.17-1.38 (m, 5H, H-6, H-8, H-2’), 1.42-1.52 (m, 3H, H-4, H-7, H-1’), 1.46 (s, 9H, tBu), 
1.53-1.94 (m, 7H, H-3, H-4a, H-5, H-7, H-8, H-1’), 3.70-3.76 (m, 1H, H-2), 3.88 (dt, J = 12.0, 4.4 Hz, 
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1H, H-8a); 13C NMR (75.4 MHz, CDCl3) δ 14.1 (CH3), 19.1 (CH3), 19.8 (C-4), 19.9 (C-7), 20.4 (C-2’), 
22.6 (C-3), 26.0 (C-6), 28.6 (3CH3-tBu), 29.9 (C-8), 33.1 (C-5), 36.5 (C-4a), 37.6 (C-1’), 49.9 (C-2), 
50.9 (C-8a), 78.6 (C-tBu), 155.1 (NCO); IR (NaCl) 1688 cm-1; [α]22D +14.7 (c 0.9, MeOH); Anal. Calcd 
for C18H33NO2: C 73.17, H 11.26, N 4.74; found: C 72.84, H 11.65, N 4.74. To a solution of the above 
saturated compound (100 mg, 0.34 mmol) in anhydrous CH2Cl2 (2 mL) was added TFA (0.5 mL, 26 
mmol), and the mixture was stirred at rt for 15 min. Then, CH2Cl2 (3 mL) was added, and the solution 
was washed with 10% aqueous KOH, dried, and concentrated to give ent-2-epi-pumiliotoxin C (65 mg, 
100%) as a colorless oil: 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 0.88-0.92 (t, J = 6.8 Hz, 3H, H-
3’), 0.98-1.00 (d, J = 7.2 Hz, 3H, CH3), 1.06-2.05 (m, 16H), 2.79-2.82 (m, 1H, H-2), 3.10-3.15 (dt, J = 
10.8, 4.1 Hz, 1H, H-8a); 13C NMR (75.4 MHz, CDCl3) δ 14.2 (C-3’), 19.2 (C-4), 19.3 (CH3), 20.5 (C-
7), 25.2 (C-3), 28.3 (C-8), 29.7 (CH2), 31.4 (CH2), 32.5 (C-5), 38.3 (C-1’), 41.8 (C-4a), 49.6 (C-2), 50.0 
(C-8a); IR (NaCl) 2859 cm-1; [α]22D −22.2 (c 0.6, MeOH).  For the hydrochloride: mp 230-235 ºC; 
[α]22D −13.3 (c 1.1, MeOH). 
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